艾意凯咨询（L.E.K.）：2024年从利基市场到广泛使用：放射治疗的转折点报告（英文版）

Radiopharmaceuticals have the potential to transition to mainstream use, driven by their dual role in diagnostics and therapy, especially in oncology. 2. Recent commercial success with beta-emitting treatments like Lutathera and Pluvicto signal strong growth, while a rich overall pipeline increasingly diversifies towards emerging alpha-emitting isotopes and novel ligand targets. 3. Biopharma companies interested in radiotherapeutics need to carefully assess investment in the right innovation are